25 related articles for article (PubMed ID: 38614382)
1. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
Chapagai D; Ramamoorthy G; Varghese J; Nurmemmedov E; McInnes C; Wyatt MD
J Med Chem; 2021 Jul; 64(14):9916-9925. PubMed ID: 34210138
[TBL] [Abstract][Full Text] [Related]
3. Diosgenin potentiates the anticancer effect of doxorubicin and volasertib via regulating polo-like kinase 1 and triggering apoptosis in hepatocellular carcinoma cells.
Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):4883-4894. PubMed ID: 38165424
[TBL] [Abstract][Full Text] [Related]
4. Potent Synergistic Effect on C-Myc-Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a Plk1 Inhibitor.
Xie Y; Zhang W; Guo L; Kril LM; Begley KL; Sviripa VM; Chen X; Liu X; Lee EY; He D; Wang C; Gao T; Liu X; Evers BM; Watt DS; Liu C
Mol Cancer Ther; 2021 Oct; 20(10):1893-1903. PubMed ID: 34376582
[TBL] [Abstract][Full Text] [Related]
5. Plk1 phosphorylation of Numb leads to impaired DNA damage response.
Shao C; Chien SJ; Farah E; Li Z; Ahmad N; Liu X
Oncogene; 2018 Feb; 37(6):810-820. PubMed ID: 29059161
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
Tang Q; Hu G; Sang Y; Chen Y; Wei G; Zhu M; Chen M; Li S; Liu R; Peng Z
Clin Transl Med; 2024 May; 14(5):e1703. PubMed ID: 38769666
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers.
Takahashi T; Sano B; Nagata T; Kato H; Sugiyama Y; Kunieda K; Kimura M; Okano Y; Saji S
Cancer Sci; 2003 Feb; 94(2):148-52. PubMed ID: 12708489
[TBL] [Abstract][Full Text] [Related]
8. GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitors.
Thorne CA; Wichaidit C; Coster AD; Posner BA; Wu LF; Altschuler SJ
Nat Chem Biol; 2015 Jan; 11(1):58-63. PubMed ID: 25402767
[TBL] [Abstract][Full Text] [Related]
9. Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.
Cristóbal I; Rojo F; Madoz-Gúrpide J; García-Foncillas J
Mol Cell Biol; 2016 Jun; 36(12):1734-9. PubMed ID: 27090640
[TBL] [Abstract][Full Text] [Related]
10. Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.
Cholewa BD; Pellitteri-Hahn MC; Scarlett CO; Ahmad N
J Proteome Res; 2014 Nov; 13(11):5041-50. PubMed ID: 24884503
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinases inhibitors.
Garuti L; Roberti M; Bottegoni G
Curr Med Chem; 2012; 19(23):3937-48. PubMed ID: 22709006
[TBL] [Abstract][Full Text] [Related]
12. Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
Wang Y; Wang G; Xiang W; Liu X; Jiang M; Hu J
Eur J Pharmacol; 2024 Jun; 972():176558. PubMed ID: 38614382
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
14. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
15. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer.
Solanes-Casado S; Cebrián A; Rodríguez-Remírez M; Mahíllo I; García-García L; Río-Vilariño A; Baños N; de Cárcer G; Monfort-Vengut A; Castellano V; Fernández-Aceñero MJ; García-Foncillas J; Del Puerto-Nevado L
Biomed Pharmacother; 2021 Dec; 144():112347. PubMed ID: 34700228
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
